Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (582)	6/2/1999 3:45:00 PM
From: sim1	Read Replies (1) \| Respond to of 1494

Heard an advertisement on the radio this morning trying to recruit patients for a clinical trial for diabetic neuropathy. Out of curiosity I called their 800 number to ask the name of the drug. All they knew was that Parke-Davis (Warner-Lambert) was conducting the trial. According to a (May 18) Reuters news release there are two large pivotal trials underway for Zenarestat for diabetic neuropathy. Any thoughts on competitive aspects between memantine and WLA's compound? If these drugs address different indications or markets, any chance WLA could be a potential partner for memantine, perhaps to strengthen the pain management franchise they seem to be developing? techstocks.com